These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1448851)

  • 1. Relationship between serum concentration and dose of valproic acid during monotherapy in adult outpatients.
    Tisdale JE; Tsuyuki RT; Oles KS; Penry JK
    Ther Drug Monit; 1992 Oct; 14(5):416-23. PubMed ID: 1448851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy.
    Gidal BE; Pitterle ME; Spencer NW; Maly MM
    J Clin Pharm Ther; 1995 Aug; 20(4):215-9. PubMed ID: 8557785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of free serum valproate concentration: A prospective study in patients on divalproex sodium monotherapy.
    Nasreddine W; Dirani M; Atweh S; Makki A; Beydoun A
    Seizure; 2018 Jul; 59():24-27. PubMed ID: 29730272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy.
    Mei S; Feng W; Zhu L; Yu Y; Yang W; Gao B; Wu X; Zhao Z; Fang F
    Seizure; 2017 Oct; 51():22-26. PubMed ID: 28763744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Influencing Sodium Valproate Serum Concentrations in Patients with Epilepsy Based on Logistic Regression Analysis.
    Lan X; Mo K; Nong L; He Y; Sun Y
    Med Sci Monit; 2021 Nov; 27():e934275. PubMed ID: 34776507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproic acid concentration and biochemical indexes in epilepsy outpatients during monotherapy or combination therapy.
    Yang X; Wang P; Pan J; Wang C; Luo J; Ma H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Jul; 45(7):782-789. PubMed ID: 32879081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling.
    Vucićević K; Miljković B; Pokrajac M; Prostran M; Martinović Z; Grabnar I
    Eur J Pharm Sci; 2009 Dec; 38(5):512-8. PubMed ID: 19804822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of saliva and serum free valproic acid concentrations in persons with epilepsy.
    Dwivedi R; Gupta YK; Singh M; Joshi R; Tiwari P; Kaleekal T; Tripathi M
    Seizure; 2015 Feb; 25():187-90. PubMed ID: 25455060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of UGT1A6 and GABRA1 on Standardized Valproic Acid Plasma Concentrations and Treatment Effect in Children With Epilepsy in China.
    Feng W; Mei S; Zhu L; Yu Y; Yang W; Gao B; Wu X; Zhao Z; Fang F
    Ther Drug Monit; 2016 Dec; 38(6):738-743. PubMed ID: 27855134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy.
    Itoh H; Suzuki Y; Fujisaki K; Sato Y; Takeyama M
    Biol Pharm Bull; 2012; 35(6):971-4. PubMed ID: 22687541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring Protein-Unbound Valproic Acid Serum Concentrations in Clinical Practice.
    Wallenburg E; Klok B; de Jong K; de Maat M; van Erp N; Stalpers-Konijnenburg S; Essink G; van Luin M
    Ther Drug Monit; 2017 Jun; 39(3):269-272. PubMed ID: 28437285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety range of free valproic acid serum concentration in adult patients.
    Tseng YJ; Huang SY; Kuo CH; Wang CY; Wang KC; Wu CC
    PLoS One; 2020; 15(9):e0238201. PubMed ID: 32877431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsia; 1996 Dec; 37(12):1200-3. PubMed ID: 8956852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the Variables Influencing Valproic Acid Concentration in the Serum and Cerebrospinal Fluid of Chinese Patients After Craniotomy.
    Li Z; Gao W; Liu G; Chen W
    Ther Drug Monit; 2017 Aug; 39(4):450-456. PubMed ID: 28604475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empirical approach for improved estimation of unbound serum concentrations of valproic acid in epileptic infants by considering their physical development.
    Ueshima S; Aiba T; Sato T; Matsunaga H; Kurosaki Y; Ohtsuka Y; Sendo T
    Biol Pharm Bull; 2011; 34(1):108-13. PubMed ID: 21212527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Derivation and evaluation of an equation for prediction of free phenytoin concentration in patients co-medicated with valproic acid.
    Haidukewych D; Rodin EA; Zielinski JJ
    Ther Drug Monit; 1989; 11(2):134-9. PubMed ID: 2497562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of total and free valproic acid during monotherapy in infants.
    Herngren L; Lundberg B; Nergårdh A
    J Neurol; 1991 Sep; 238(6):315-9. PubMed ID: 1940980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the pharmacokinetics of total and free valproate in mono- and bitherapy with carbamazepine in epileptic children and adolescents.
    Steinborn B; Galas-Zgorzalewicz B
    Folia Neuropathol; 2002; 40(2):97-100. PubMed ID: 12230261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproic acid clearance in children with epilepsy.
    Sánchez-Alcaraz A; Quintana MB; López E; Rodríguez I
    J Clin Pharm Ther; 1998 Feb; 23(1):31-4. PubMed ID: 9756109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring free valproic acid in epilepsy patients medicated with coanticonvulsants.
    Haidukewych D; Rodin EA
    Ther Drug Monit; 1982; 4(2):209-12. PubMed ID: 6808716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.